These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36938094)

  • 1. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
    Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
    Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy.
    Zan J; Liu L; Li G; Zheng H; Chen N; Wang C; Xie D; Zuo L; Li R; Zhang P; Wang Y; Wang W; Li L; Fang J; Lv J; Zhang H
    Kidney Int Rep; 2024 Apr; 9(4):1067-1071. PubMed ID: 38765591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telitacicept: First Approval.
    Dhillon S
    Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of telitacicept in the treatment of IgA nephropathy.
    Wu L; Du X; Lu X
    Eur J Med Res; 2023 Sep; 28(1):369. PubMed ID: 37737205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.
    Ji L; Geng Y; Zhang X; Deng X; Song Z; Tan M; Tan Y; Qu C; Zhang Z
    MedComm (2020); 2024 Apr; 5(4):e515. PubMed ID: 38525109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.
    Barratt J; Tumlin J; Suzuki Y; Kao A; Aydemir A; Pudota K; Jin H; Gühring H; Appel G;
    Kidney Int Rep; 2022 Aug; 7(8):1831-1841. PubMed ID: 35967104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
    Ma X; Fu X; Cui B; Lin H
    Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial.
    Li P; Lin H; Ni Z; Zhan Y; He Y; Yang H; Fang J; Wang N; Li W; Cai G; Chen Y; Zhang P; Wang X; Chen Q; Li Z; Sun X; Chen X
    Phytomedicine; 2020 May; 76():153231. PubMed ID: 32535481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
    Xu D; Fang J; Zhang S; Huang C; Huang C; Qin L; Li X; Chen M; Liu X; Liu Y; Li Z; Hu J; Bao C; Wei W; Tian J; Duan X; Zeng X
    Rheumatology (Oxford); 2024 Mar; 63(3):698-705. PubMed ID: 37399108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
    Xie J; Fan X; Su Y; Zhou H; Cao S; Zhu X; Zhu M; He C; Wang Y; Fan L; Ge Q; Zhu J; Liu B; Chen X; Xie Y; Ma L; Liu Y; Chen J; Wang H; Li Z
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1273-1283. PubMed ID: 35844038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report.
    Du X; Tian G; Lu X
    BMC Pregnancy Childbirth; 2024 Jun; 24(1):432. PubMed ID: 38886682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of telitacicept in patients with lupus nephritis.
    Zhu H; Hu HQ; Wei HL; Zhang DX; Yang H; Zhang QK; Jin L
    Exp Ther Med; 2024 Oct; 28(4):371. PubMed ID: 39091632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
    Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
    Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF; Xie D; Wang J; Xu X; Yang X; Ai J; Nie S; Liang M; Wang G; Jia N;
    JAMA Netw Open; 2023 Feb; 6(2):e2254054. PubMed ID: 36745456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
    JAMA; 2022 May; 327(19):1888-1898. PubMed ID: 35579642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
    Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.